Susvimo Shows Long-Term Benefits in Treating Wet AMD

Roche reported positive five-year effectiveness, safety, and durability data for Susvimo (ranibizumab injection) for the treatment of neovascular or "wet" age-related macular degeneration (nAMD) from the Phase III Portal study, a long-term extension of the Phase III Archway research.

According to the statistics, Susvimo's effectiveness and durability were maintained for five years, with about 95% of patients who received therapy every six months not requiring any additional care in between refills. The findings were showcased at the 2025 Annual Meeting of the American Society of Retina Specialists (ASRS) in Long Beach, California.

“These results reinforce Susvimo’s ability to maintain vision and retinal dryness over a long period for people with nAMD, the leading cause of vision loss in people over 60,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “The data support Susvimo as an effective alternative to frequent eye injections.”

Also Read: Sun Pharma Introduces Dry Eye Treatment Medication

John Kitchens, M.D., Retina Associates of Kentucky, who presented the data, said: “In real-world practice, people with nAMD often have suboptimal outcomes due to the burden of frequent injections. Continuous delivery with Susvimo may help maintain vision for longer compared to traditional intravitreal (IVT) injections.” In contrast to monthly injections, Susvimo provides continuous drug delivery directly into the eye to treat retinal conditions that can lead to vision loss. It does this by administering a customized formulation of ranibizumab through the Port Delivery Platform, a refillable eye implant placed in a single outpatient procedure.